Activation of hepatocyte growth factor by urokinase-type plasminogen activator is ionic strength-dependent

被引:11
|
作者
Mars, WM
Jo, M
Gonias, SL
机构
[1] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA
[2] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA
关键词
epsilon-amino-caproic acid (EACA); hepatocyte growth factor (HGF); HGF receptor (MET); ionic strength; urokinase-type plasminogen activator (u-PA); u-PA receptor (u-PAR);
D O I
10.1042/BJ20042028
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The hepatocyte growth factor (HGF) is a multifunctional cytokine that is produced as latent scHGF (single chain HGF). Various proteases reportedly cleave scHGF to generate the active two-chain form (HGF), including u-PA (urokinase-type plasminogen activator), t-PA (tissue-type plasminogen activator), kallikrein, Factor XIa, Factor XIIa, HGF activator and matriptase. Considerable evidence indicates that, in vivo, u-PA activates scHGF in the liver; however, the in vivo results have not been uniformly supported by in vitro experiments. We now report that cleavage of scHGF by high-molecular-mass u-PA (abbreviated u-PA throughout) is sensitive to ionic strength. scHGF cleavage by u-PA was accelerated as the ionic strength was decreased. This result was equivalent irrespective of whether the predominant anion was chloride or acetate. Lmw-u-PA (low-molecular-mass u-PA) was ineffective at cleaving scHGF, regardless of ionic strength. Although scHGF shares homology with plasminogen, EACA (epsilon-amino-caproic acid) did not regulate u-PA-mediated scHGF cleavage. Soluble HGF receptor (MET) and soluble u-PAR (u-PA receptor) inhibited the scHGF cleavage. These results support a model in which the ability of u-PA to activate scHGF in vivo may be highly dependent on local conditions within the extracellular space.
引用
收藏
页码:311 / 315
页数:5
相关论文
共 50 条
  • [21] The Clinical Study of Urokinase-Type Plasminogen Activator and Vascular Endothelial Growth Factor in Gastric Cancer
    Xue-wen Yang
    Feng Gao
    Ya-jun Chen
    Feng-meng Teng
    Cell Biochemistry and Biophysics, 2015, 72 : 649 - 652
  • [22] Targeting epidermal growth factor receptors and urokinase-type plasminogen activator receptors for sarcoma therapy
    Graef, Ashley J.
    Kim, Jong-Hyuk
    Vallera, Daniel A.
    Modiano, Jaime F.
    CANCER RESEARCH, 2018, 78 (13)
  • [23] The Clinical Study of Urokinase-Type Plasminogen Activator and Vascular Endothelial Growth Factor in Gastric Cancer
    Yang, Xue-wen
    Gao, Feng
    Chen, Ya-jun
    Teng, Feng-meng
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2015, 72 (03) : 649 - 652
  • [24] Multiparity upregulates placental plasminogen and urokinase-type plasminogen activator
    Cortina, Maria E.
    Litwin, Silvana
    Hawila, Maria R. Rial
    Miranda, Silvia
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2017, 77 (04)
  • [25] Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells
    Nishimura, K
    Matsumiya, K
    Miura, H
    Tsujimura, A
    Nonomura, N
    Matsumoto, K
    Nakamura, T
    Okuyama, A
    INTERNATIONAL JOURNAL OF ANDROLOGY, 2003, 26 (03): : 175 - 179
  • [26] Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system
    Yin, SP
    Lockett, J
    Meng, YH
    Biliran, H
    Blouse, GE
    Li, XH
    Reddy, N
    Zhao, ZM
    Lin, XL
    Anagli, J
    Cher, ML
    Sheng, SJ
    CANCER RESEARCH, 2006, 66 (08) : 4173 - 4181
  • [27] Activation of the Zymogen to Urokinase-Type Plasminogen Activator Is Associated with Increased Interdomain Flexibility
    Behrens, Manja A.
    Botkjaer, Kenneth A.
    Goswami, Sumit
    Oliveira, Cristiano L. P.
    Jensen, Jan K.
    Schar, Christine R.
    Declerck, Paul J.
    Peterson, Cynthia B.
    Andreasen, Peter A.
    Pedersen, Jan Skov
    JOURNAL OF MOLECULAR BIOLOGY, 2011, 411 (02) : 417 - 429
  • [28] Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B
    Zhou, Huanqin
    Wu, Xianguo
    Lu, Xingguo
    Chen, Gang
    Ye, Xiongwei
    Huang, Jian
    THROMBOSIS RESEARCH, 2009, 123 (03) : 537 - 542
  • [29] Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation
    Abraham, E
    Gyetko, MR
    Kuhn, K
    Arcaroli, J
    Strassheim, D
    Park, JS
    Shetty, S
    Idell, S
    JOURNAL OF IMMUNOLOGY, 2003, 170 (11): : 5644 - 5651
  • [30] Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation
    Sun, ZY
    Zhang, PX
    Wang, P
    Gurewich, V
    Shen, HY
    Liu, JN
    THROMBOSIS RESEARCH, 2002, 106 (02) : 105 - 111